The recent Blood 2018 meeting in Brisbane was definitely a highlight of this year.
The meeting brings together scientists and clinicians from all over Australia and the world to discuss emerging paradigms and breakthroughs at the forefront of research and treatments of blood cancer to new therapies emerging in the clinic.
This year, the ALLG had the opportunity to set up a display booth outlining our most recent clinical trials and to raise awareness of who we are by promoting our work in blood cancer clinical trial research.
Hosted by the Haematology Society of Australia and New Zealand, the Australian and New Zealand Society of Blood Transfusion, and the Thrombosis and Haemostasis Society of Australia and New Zealand, the Blood Meetings are highly successful and one of the premier assemblies combining early-career investigators and senior scientists.
The comprehensive program ensured a broad representation from each of the five societies, and speakers from all states in Australia and New Zealand as well as the invited overseas guests.
Representing the ALLG was Prof David Curtis presenting an update on ALLG clinical trial BM12, a randomised phase 3 trial of cyclophosphamide after sibling allogeneic haematopoietic stem cell transplant, and A/Prof Hang Quach presenting a preliminary analysis of the ALLG international clinical trial MM18, a Single arm multicentre study of carfilzomib thalidomide dexamethasone for relapsed/refractory multiple myeloma.
International keynote speakers included:
- Kate Pendry, Clinical Director for Patient Blood Management, NHS Blood and Transplant, UK
- Harvey Klein, Chief, Department of Transfusion Medicine, NIH Clinical Center, USA
- Thierry Peyrard, Director, National Immunohematology Reference Laboratory, National Institute of Blood Transfusion, Paris
Convener Associate Professor Steven Lane said the program was very diverse with leading speakers from some of the most exciting areas in haematology.
“Stan Riddell for example is one of the driving forces behind the development of CAR T cells and widely acknowledged as one of the world’s experts.”
“We also had great clinical trials specialists like Ann LaCasce in lymphoma and Steven Coutré, an expert in chronic leukaemia, and we have a couple of internationally renowned myeloma specialists coming out in Gareth Morgan and Ola Landgren”, said A/Prof Lane.
Another highlight of the meeting was ALLG’s participation in the Blood Cancer Forum on Tuesday morning. The forum representatives include the Australasian Leukaemia & Lymphoma Group, Haematology Society of Australia and New Zealand, Leukaemia Foundation Australia, Lymphoma Australia, Myeloma Australia, and Snowdome Foundation.
ALLG CEO, Delaine Smith said for the Australian research community to advance knowledge, improve clinical practices, and progress better treatments it is critical that these types of forums exists.
“The purpose of the Blood Cancer Forum is to improve outcomes for patients with blood cancers.”
“We do this through utilising our individual organisations strengths in a non-partisan approach to advance our unified cause – better outcomes and experiences for people affected by blood cancers.”
“When research cannot be advanced it becomes a difficult situation for the patient, the doctor, the hospital and the funders e.g. Federal Government and private insurance. Overcoming this barrier has been a unifying impetus for the formation of the Blood Cancer Forum”, said Ms Smith.
On behalf of the ALLG, we would like to congratulate the organising committee on the presentation and conduct of the Blood 2018 meeting in Brisbane. The venue was ideal and provided a layout perfect for the event. Further, the speakers were of superb calibre with the session content interesting, engaging and informative.
We would also like to thank the organising committee for the ALLG exhibitor booth. We very much value the support provided and believe it was of great benefit for the ALLG to network and raise the profile of investigator initiated clinical trials in Australia.
The next Blood meeting will be held in Perth 2019.